Tscan Therapeutics, Inc. · NASDAQ:TCRX

Tscan Therapeutics — Investor Presentation (September 2026)

22 slides from Tscan Therapeutics's investor presentation, September 2026

  1. Slide 1: Corporate Presentation September 2026

    Corporate Presentation September 2026

  2. Slide 2: Disclaimers and forward-looking statements

    Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.'

  3. Slide 3: Strategic prioritization to focus on in vivo cell therapy for solid tumor indications

    Strategic prioritization to focus on in vivo cell therapy for solid tumor indications TScan today Strategy Value inflection points • In vivo lentivirus platform • Preclinical data and regulatory • Focus on advancing PRAME and updates – Q1 2027 SOLID developed MAGE-A4 TCR-Ts with in vivo TUMORS • Two

  4. Slide 4: Focus on in vivo-engineered TCR-T cell therapies for solid tumors

    Focus on in vivo-engineered TCR-T cell therapies for solid tumors Indications Program (Targets) Discovery IND-enabling Phase 1 In vivo-engineered TCR-T cell therapies Undisclosed TSC-303-A02 (PRAME) SOLID TUMORS Undisclosed TSC-302-A02 (MAGE-A4) Undisclosed TSC-303-A24 (PRAME) Engineered TCR-T cell

  5. Slide 5: Solid Tumors

    Solid Tumors Developing in vivo-engineered TCR-T cell therapy for solid tumor indications

  6. Slide 6: Solid tumors represent a large unmet medical need

    Solid tumors represent a large unmet medical need THE UNMET NEED TARGETABLE BIOLOGY High mortality persists in solid tumor indications TScan's TCR-T therapies target prevalent cancer- despite approved therapies specific antigens in major solid tumor indications 550,000 deaths from solid tumor indica

  7. Slide 7: Lentiviral-based in vivo engineering technology addresses the key challenges of autologous TCR-T cell therapy

    Lentiviral-based in vivo engineering technology addresses the key challenges of autologous TCR-T cell therapy In vivo engineering solves the key In vivo lentiviral approach offers challenges of autologous TCR-T potential for long-term responses • No patient-specific manufacturing, • T cell-targeted

  8. Slide 8: Early data from in vivo CAR-T programs in heme malignancies show remarkable response rates

    Early data from in vivo CAR-T programs in heme malignancies show remarkable response rates PROOF-OF-CONCEPT IN HEME MALIGNANCY SPACE In vivo-engineered CAR-T programs are showing deep responses and durable T-cell persistence BCMA CAR-T BCMA CAR-T CD19xCD20 CAR-T Relapsed/refractory Relapsed/refracto

  9. Slide 9: In vivo-engineered TCR-T provide a promising way to address solid tumor indications

    In vivo-engineered TCR-T provide a promising way to address solid tumor indications TCR-T cells recognize cancer-specific antigens presented on HLA Class I PRAME is expressed at high levels T cell in cutaneous melanoma* TCR Target antigen (e.g., PRAME) CD8α/β HLA class I (e.g., A*02:01) Tumor cell *

  10. Slide 10: MAGE-A4 TCR delivered in vivo shows tumor clearance in PBMC-engrafted mice

    MAGE-A4 TCR delivered in vivo with an early version of a targeted lentivirus shows tumor clearance in PBMC-engrafted mice implanted with NSCLC tumor model Engraft PBMCs Readout: Implant Tumor LVV test (1x10M) Dose with LVV Tumor volume conditions NCG, MHC Day 0 Day 13 Day 14 Day 21 Day 50 DKO mice D

  11. Slide 11: TScan's third generation lentiviral vector enables in vivo generation of TCR-T cells

    TScan’s third generation lentiviral vector enables in vivo generation of TCR-T cells • T-cell targeting antibodies direct the Proprietary elements virus to cytotoxic and helper T-cells Non-targeting • Antibodies simultaneously target and fusogen activate T-cells, enabling rapid expansion in vivo Dua

  12. Slide 12: Solid tumor program on track to initiate Phase 1 development in Q4 2027

    Solid tumor program on track to initiate Phase 1 development in Q4 2027 UPCOMING MILESTONES Q2 2026 Q1 2027 Q3 2027 INTERACT meeting with • Present preclinical data File first IND U.S. FDA • Provide regulatory update Q3 2026 Q2 2027 Q4 2027 • Lead candidates Initiate GMP production Initiate Phase 1

  13. Slide 13: Heme Malignancies

    Heme Malignancies Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT

  14. Slide 14: TSC-101 is designed to target residual disease and prevent relapse in patients undergoing HCT

    TSC-101 is designed to target residual disease and prevent relapse in patients undergoing hematopoietic cell transplantation HLA A*02:01-positive (HA-2-positive) * * Patient identification Day -10 to -1 Day 0 Day 21 Day 61 Follow up Reduced Intensity HCT transplant Infusion 1 Infusion 2 Conditioning

  15. Slide 15: Patients generally well balanced across TSC-101 and control arms

    Patients generally well balanced across TSC-101 and control arms although Cohort C included a higher percentage of high-risk patients TSC-101 TSC-101 Control Cohort A Cohort C Evaluable Subjects* 19 14 19 Age, Median years (Range) 65 (52-74) 68 (28-79) 66 (23-77) Sex, Male 13 (68%) 9 (64%) 9 (47%) A

  16. Slide 16: Pre-transplant MRD is associated with a very high risk of relapse in AML patients

    Pre-transplant MRD is associated with a very high risk of relapse in AML patients • Retrospective analysis of 392 patients with AML(1) • Retrospective analysis of adults with AML (n = 1,114) who received • All patients received NMA- or RIC-HCT their first allo-transplant between April 2006 and March

  17. Slide 17: All 14 Cohort C patients were at high risk of relapse

    All 14 Cohort C patients were at high risk of relapse: 12 were MRD-positive and remaining 2 were p53m Dose level Disease HCT Pre-HCT MRD TSC-101 infusion DL4 AML-p53m Haplo 1 P-004-0022 DL4 MDS Haplo MRD-positive 2 P-007-0012 MRD-negative DL3 AML MMUD 3 P-013-0014 MRD pending DL4 AML Haplo 4 P-014-0

  18. Slide 18: All patients in Cohort C had complete donor chimerism at last assessment

    Despite being at high risk of relapse, all patients in Cohort C had complete donor chimerism at their last assessment, including both patients who relapsed 1 2 3 4 5 6 7 8 9 10 11 12 13 14 04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 27-004 16-003 13-017 13-019 DL4 DL4 DL3 D

  19. Slide 19: All patients in Cohort C had complete donor chimerism at last assessment

    Despite being at high risk of relapse, all patients in Cohort C had complete donor chimerism at their last assessment, including both patients who relapsed Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 p53m-AML MDS MECOM-AML AML p53m-ALL p53m-MDS AML MRD- MRD+ MRD+ 4 MRD+ MRD

  20. Slide 20: TSC-101 is well tolerated with no dose-limiting toxicity

    TSC-101 is well tolerated with no dose-limiting toxicity • No dose-limiting toxicities were observed across either Cohort A Cohort C Control treatment cohort n=19 n=14 n=19 Treatment-emergent acute GvHD (MAGIC) 14 (73.7%) 5 (35.7%) 12 (63.2%) • Treatment-emergent acute GvHD occurred in most Grade I

  21. Slide 21: Upcoming milestones

    Upcoming milestones 2026 H1 2027 H2 2027 Solid Tumor Initiated IND-enabling studies Present preclinical data of in vivo-engineered TCR-Ts File first IND for in vivo- engineered TCR-T for 2 in vivo TCR-T candidates Program (Q3 2027) Initiate Phase 1 development of in vivo-engineered TCT-T (Q4 2027) H

  22. Slide 22: THANK YOU

    THANK YOU

TScan Therapeutics — Investor Presentation (September 2026) on 6ix